NC
NERV icon

Northpointe Capital’s Minerva Neurosciences NERV Stock Holding History

Northpointe Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,260
Closed -$607K – 135
2018
Q4 		$607K Sell
11,260
-24,070
-68% -$1.76M 0.14% 162
2018
Q3 		$3.55M Buy
35,330
+3,356
+10% +$252K 0.51% 90
2018
Q2 		$2.11M Buy
+31,974
New +$1.94M 0.28% 153

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return

Northpointe Capital's NERV Position: Q1 2019 in Review

Northpointe Capital sold out of Minerva Neurosciences (NERV) in Q1 2019, closing a stake of 11,260 shares — an estimated $607K sold.

Northpointe Capital first reported a position in NERV in Q2 2018 and held it in 3 quarters. The position peaked at $3.55M in Q3 2018. 79 funds tracked by Wall St. Rank hold NERV as of Q1 2019.

  • Northpointe Capital reported no remaining Minerva Neurosciences position as of Q1 2019 after selling out during the quarter.
  • Northpointe Capital sold 11,260 Minerva Neurosciences shares in Q1 2019, an estimated $607K.
  • Northpointe Capital first reported a position in Minerva Neurosciences in Q2 2018 and held it in 3 quarters.
  • Northpointe Capital's Minerva Neurosciences position peaked at $3.55M in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2019.

Based on Northpointe Capital's 13F filing for Q1 2019, filed 17 Apr 2019.